Trial Profile
Brimonidine/Timolol Fixed Combination Prophylaxis for Intraocular Pressure Elevation Following Intravitreal Injection of Antivascular Endothelial Growth Factor
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 24 May 2023
Price :
$35
*
At a glance
- Drugs Brimonidine/timolol (Primary)
- Indications Ocular hypertension
- Focus Therapeutic Use
- 19 May 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 17 Aug 2018 Planned End Date changed from 1 Jun 2019 to 1 Sep 2019.
- 17 Aug 2018 Planned primary completion date changed from 1 Jan 2019 to 1 Apr 2019.